Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors.
biomarker
cancer immunotherapy
extracellular vesicles
immune checkpoint inhibitors
non-small cell lung cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Feb 2021
03 Feb 2021
Historique:
received:
29
12
2020
revised:
22
01
2021
accepted:
28
01
2021
entrez:
6
2
2021
pubmed:
7
2
2021
medline:
7
2
2021
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) induce durable clinical responses only in a subset of advanced non-small cell lung cancer (NSCLC) patients. There is a need to identify mechanisms of ICI resistance and immunotherapy biomarkers to improve clinical benefit. In this study, we evaluated the prognostic and predictive value of circulating endothelial and leukocyte-derived extracellular vesicles (EV) in patients with advanced NSCLC treated with anti-PD-1/PD-L1 agents. In addition, the relationship between total blood circulating EV proteome and response to ICIs was investigated. An optimized flow cytometry method was employed for the identification and subtyping of blood circulating EVs in 59 patients with advanced NSCLC. Blood samples were collected from patients receiving anti-PD-1/PD-L1 inhibitors (
Identifiants
pubmed: 33546102
pii: cancers13040585
doi: 10.3390/cancers13040585
pmc: PMC7913165
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Mol Sci. 2019 Aug 18;20(16):
pubmed: 31426571
Cancer Med. 2018 May;7(5):2013-2020
pubmed: 29601673
Nat Rev Clin Oncol. 2019 Jun;16(6):341-355
pubmed: 30718843
Int J Mol Sci. 2020 Dec 23;22(1):
pubmed: 33374539
Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19461-6
pubmed: 20978210
J Immunother Cancer. 2019 Dec 5;7(1):343
pubmed: 31806053
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Med Oncol. 2019 Nov 11;37(1):2
pubmed: 31713115
Br J Cancer. 2018 Mar 20;118(6):820-824
pubmed: 29509748
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Eur J Immunol. 2019 Oct;49(10):1457-1973
pubmed: 31633216
Sci Rep. 2016 May 09;6:25689
pubmed: 27157262
Cell. 2019 Apr 4;177(2):414-427.e13
pubmed: 30951669
Platelets. 2017 May;28(3):256-262
pubmed: 28277059
Cancers (Basel). 2019 Dec 21;12(1):
pubmed: 31877735
Exp Mol Med. 2020 Sep;52(9):1475-1485
pubmed: 32913278
Nat Rev Clin Oncol. 2018 Oct;15(10):617-638
pubmed: 29795272
Front Med (Lausanne). 2020 Mar 24;7:90
pubmed: 32266275
AIDS. 2021 Mar 15;35(4):595-604
pubmed: 33306552
J Oncol. 2019 Nov 18;2019:5879616
pubmed: 31827511
Blood. 1996 Jul 15;88(2):667-73
pubmed: 8695814
Anticancer Res. 2018 Jul;38(7):3789-3796
pubmed: 29970498
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9824-9
pubmed: 11504947
J Oncol. 2019 Jun 9;2019:1639854
pubmed: 31281356
Cancer J. 2018 Jan/Feb;24(1):47-53
pubmed: 29360728
J Thorac Oncol. 2020 Nov;15(11):1773-1781
pubmed: 32565389
Nat Rev Immunol. 2011 Sep 23;11(10):702-11
pubmed: 21941296
J Immunother Cancer. 2019 Nov 27;7(1):325
pubmed: 31775882
Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):E1101-10
pubmed: 24616502
Methods Mol Biol. 2018;1711:133-148
pubmed: 29344888
J Proteomics. 2019 Jul 30;204:103403
pubmed: 31170500
Sci Rep. 2020 Jan 23;10(1):1039
pubmed: 31974468
Clin Cancer Res. 2019 Aug 1;25(15):4592-4602
pubmed: 30824587
Mol Cancer. 2019 Mar 30;18(1):59
pubmed: 30925927
Cancer Res. 2003 May 1;63(9):2322-9
pubmed: 12727857
Sci Rep. 2018 Feb 15;8(1):3071
pubmed: 29449691
Int J Biol Sci. 2016 Nov 25;12(12):1472-1487
pubmed: 27994512
World J Gastroenterol. 2020 May 14;26(18):2126-2137
pubmed: 32476780
Int J Mol Sci. 2020 Oct 23;21(21):
pubmed: 33114229
Cancer Immunol Res. 2014 Jan;2(1):50-8
pubmed: 24778162
Annu Rev Immunol. 2018 Apr 26;36:435-459
pubmed: 29400984
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690